In the past decade, ICB targeting PD-1, PD-L1, or CTLA-4 has proven effective against a variety of solid tumor malignancies as well as Hodgkin lymphoma, and there was optimism that ICB would be successful in GCB lymphomas as well. The gene discussed is CD274; the disease is Hodgkins lymphoma.